Webb1 mars 2024 · WATERTOWN, Mass., March 01, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein … Webb3 dec. 2024 · We will support INOVIO to produce, manufacture and scale their COVID-19 candidate, INO-4800. INOVIO has assembled a global coalition of collaborators, partners and funders to rapidly advance the development of INO-4800, a DNA vaccine against …
Kaneka Eurogentec will manufacture INOVIO’s DNA vaccine …
Webb9 jan. 2024 · On December 15, Kaneka Corporation concluded a license agreement with Med Alliance SA, hereinafter referred to as “MA”, for the introduction of technology relevant to coronary drug-coated balloons (hereinafter referred to as “DCB”). Kaneka aims to … Webb14 nov. 2014 · Kaneka obtains technology license using phosphorescent materials License agreement concluded with Universal Display Corporation Jan. 20, 2014 News Release Kaneka OLED lighting panels adopted at “Admired from Afar: Masterworks of Japanese … unterschied exanthem erythem
Press Releases Kymera Therapeutics, Inc.
Webb18 okt. 2024 · Kaneka has invested in AB-Biotics SA, a Spanish biotech company and concluded a license agreement for production and sales of its probiotics products. May. 10, 2024 News Release Kaneka’s wall-mounted solar panels adopted for temporary fencing … Webb31 mars 2024 · Kaneka is the first company in the world to successfully commercialize KANEKA Biodegradable Polymer Green Planet TM ("Green Planet"), which is produced by microorganisms from vegetable oil and other raw materials. In this project, based on the … Webb12 sep. 2024 · Under the terms of the license agreement, Kiniksa will receive $100 million in upfront and near-term payments, which include $80 million within 30 days of the closing of the transaction and $20... reclaim bank fees